Scientists worldwide have been studying the role the immune system can play in fighting cancer for several decades. However, it was only recently that immuno-oncology therapies were found that provide lasting anti-cancer benefits to patients who previously had very few treatment options available to them.1-3 These therapies represent a ‘breakthrough’4 in cancer therapy and they have the potential to revolutionise the way we treat many forms of cancer.5 This leaflet aims to help patients understand what these new therapies are, how they differ from existing treatments, and what role they will play in years to come.

 

Kindly find below ECPC's on-line Guide for Patients on Immuno-Oncology for dissemination in the following 21 languages. This leaflet was developed to help patients understand more about immuno-oncology therapies, a new type of cancer treatment that uses the immune system to fight cancer: 

Bulgarian on-line Guide

Bulgarian Leaflet

Croatian on-line Guide

Croatian Leaflet

Czech on-line Guide

Czech Leaflet

Danish on-line Guide

Danish Leaflet

Dutch on-line Guide

Dutch Leaflet

English on-line Guide

 English Leaflet

Irish on-line Guide

Irish Leaflet

Estonian on-line Guide

Estonian Leaflet

French on-line Guide

French Leaflet

Greek on-line Guide

Greek Leaflet

Hungarian on-line Guide

Hungarian Leaflet

Italian on-line Guide

Italian Leaflet

Latvian on-line Guide

Latvian Leaflet 

Lithuanian on-line Guide

Lithuanian Leaflet

Polish on-line Guide

Polish artwork 

Portuguese on-line Guide

Portuguese artwork

Romanian on-line Guide

Romanian Leaflet

Slovenian on-line Guide

Slovenian Leaflet

Spanish on-line Guide

Spanish Leaflet

Swedish on-line Guide

Swedish Leaflet

Turkish on-line Guide

Turkish Leaflet

 Please write to iThis email address is being protected from spambots. You need JavaScript enabled to view it. to inform us about the activities in your respective countries.

This document has been produced by the European Expert Group on Immuno-Oncology, an independent network composed of patient organisations, cancer specialists, researchers and policymakers from across Europe who are working together to make sure that the most effective of these promising new treatments are made available to patients as quickly as possible.